StockNews.AI
SRPT
StockNews.AI
53 days

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit

1. Rosen Law Firm has filed a class action lawsuit against SRPT. 2. The lawsuit addresses misleading statements about ELEVIDYS therapy safety. 3. Investors could claim compensation without upfront fees under contingency. 4. Defendants allegedly concealed severe safety risks related to ELEVIDYS. 5. Class certification is still pending, investors can join the lawsuit.

7m saved
Insight
Article

FAQ

Why Very Bearish?

The serious allegations against SRPT could result in significant investor loss, similar to past cases like Axovant, which faced steep declines after related lawsuits were announced.

How important is it?

Legal actions like class action lawsuits can significantly influence stock prices and investor sentiment, often causing sharp downtrends as seen in previous biotech lawsuits.

Why Short Term?

The immediate concerns surrounding the lawsuit can affect SRPT's stock price rapidly as fear and uncertainty spread among investors.

Related Companies

AXGTPTCTSRNE
, /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. So What: If you purchased Sarepta Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Sarepta class action, go to https://rosenlegal.com/submit-form/?case_id=20094 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (3) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (4) as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Sarepta class action, go to https://rosenlegal.com/submit-form/?case_id=20094 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq.Phillip Kim, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827[email protected]www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News